ALS is not a form of muscular dystrophy. Although both conditions cause progressive muscle weakness, they are fundamentally different diseases with different causes, different mechanisms, and different trajectories. The confusion is understandable: both fall under the broader umbrella of “neuromuscular diseases,” and the Muscular Dystrophy Association (MDA) funds research and provides support for both. But the biology behind each one is distinct.
Where the Disease Starts
The core difference comes down to what breaks first. In ALS, the problem starts in the nervous system. Motor neurons, the nerve cells that send signals from the brain and spinal cord to your muscles, progressively die. Once those neurons are gone, muscles stop receiving instructions to move. They weaken and shrink, but the muscles themselves were healthy to begin with. The disease destroys the wiring, not the machinery.
In muscular dystrophy, the problem starts in the muscle itself. Mutations in genes responsible for building structural proteins inside muscle cells cause those cells to become fragile. One key protein, dystrophin, normally acts like an internal scaffold that holds muscle cell membranes together during contraction. Without it, every time a muscle contracts, the cell membrane tears slightly. Over months and years, muscle fibers break down and are replaced by scar tissue and fat. The nerves sending signals to those muscles are working fine; the muscles just can’t respond.
How Each Disease Feels Different
ALS typically strikes adults between the ages of 40 and 70. It often begins with weakness in one hand, one foot, or one side of the body, then spreads. Muscle twitching (fasciculations) is common early on. Because ALS affects both upper motor neurons (in the brain) and lower motor neurons (in the spinal cord), it produces a distinctive combination of symptoms: muscles that are simultaneously weak, wasted, and stiff. Slurred speech and trouble swallowing are early signs in about a quarter of cases, a pattern called bulbar onset.
Muscular dystrophy, by contrast, usually shows up in childhood, though some forms appear in adolescence or adulthood. Duchenne muscular dystrophy, the most common and severe type, is typically diagnosed between ages 2 and 5. The weakness tends to be symmetrical, affecting both sides of the body equally, and it starts in the muscles closest to the trunk: hips, thighs, shoulders, and upper arms. Children may struggle to climb stairs, get up from the floor, or run. Stiffness and exaggerated reflexes, hallmarks of ALS, are absent because the nervous system remains intact.
Different Causes, Different Genetics
Muscular dystrophy is almost always inherited. Duchenne and Becker muscular dystrophy result from mutations on the X chromosome, which is why they overwhelmingly affect boys. Other forms follow different inheritance patterns, but in nearly every case, a specific gene mutation can be identified.
ALS has a more complicated genetic picture. Roughly 90 to 95 percent of cases are sporadic, meaning they appear in people with no family history of the disease. Only 5 to 10 percent of cases are familial. Even among familial cases, more than 30 different genes have been implicated. The leading known genetic cause is a mutation in a gene called C9orf72, but for most people with ALS, the trigger remains unknown. Environmental exposures, aging, and complex gene interactions all likely play a role.
How Each Is Diagnosed
Because ALS attacks nerves rather than muscle tissue, it doesn’t show up on the blood tests or biopsies that reveal muscular dystrophy. ALS is diagnosed through a combination of clinical examination and nerve conduction studies. Doctors look for signs of both upper and lower motor neuron damage in at least one body region, using criteria known as the Gold Coast criteria. Electromyography (EMG) can detect patterns of nerve damage in muscles, including signs that nerve connections are actively breaking down. Much of the diagnostic process involves ruling out other conditions that mimic ALS.
Muscular dystrophy diagnosis takes a different path entirely. Blood tests showing elevated levels of creatine kinase, a protein that leaks out of damaged muscle cells, are often the first clue. Genetic testing can then pinpoint the exact mutation responsible. In some cases, a small muscle biopsy is taken to examine the tissue under a microscope, which can distinguish between different types of muscular dystrophy and other muscle diseases.
Progression and Life Expectancy
ALS progresses rapidly. The median survival from symptom onset is about 30 months, and from diagnosis roughly 16 months, though individual cases vary widely. Some people live several months, others more than a decade. Age at diagnosis and lung function at the time of the first clinic visit are among the strongest predictors of how quickly the disease advances. Death typically results from respiratory failure as the muscles controlling breathing lose their nerve supply.
Muscular dystrophy progresses more slowly but over a longer arc. In Duchenne muscular dystrophy, most boys lose the ability to walk by their early teens. The median life expectancy has improved significantly with modern care: people born after 1990 have a median survival of about 28 years, up from 18 years for those born before 1970. Steroid therapy, better cardiac care, and improved respiratory support account for much of that gain. Milder forms like Becker muscular dystrophy progress even more slowly, with some individuals living into their 40s, 50s, or beyond.
Why the MDA Covers Both
One reason people associate ALS with muscular dystrophy is the Muscular Dystrophy Association itself. The MDA covers a broad range of neuromuscular diseases, not just muscular dystrophies. ALS is included because it shares a common endpoint (muscle weakness and loss of function) even though the underlying mechanism is completely different. The organization takes what it calls a “big-picture perspective” on neuromuscular disease, working across conditions to find treatments and support families. This umbrella approach means ALS and muscular dystrophy often appear on the same websites and in the same fundraising campaigns, which can blur the line between them for people encountering these diseases for the first time.
The practical takeaway is straightforward: ALS and muscular dystrophy are separate diseases that happen to share some visible symptoms. One destroys the nerves that control muscles. The other destroys the muscles themselves. They differ in who they affect, when symptoms appear, how they’re diagnosed, and how they progress.